
    
      This is a phase 3, single arm, multi-center study. The patients will receive BiRd regimen
      (clarithromycin,lenalidomide, dexamethasone) combined with infusion of autologous
      BCMA-directed CAR T-cells in newly diagnosed MM patients. The study participation will be 4
      years including treatment and follow-up periods.
    
  